Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00833261 · OUTCOME

Progression Free Survival (PFS)

Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer · Source last updated 2020-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
2 year from the date of enrollment

What was measured

The 2-year PFS was measured from the date of enrollment to the first occurrence of new metastatic lesions, objective tumor progression, or death. The combination of cisplatin and cetuximab concurrent with radiation therapy for head and neck cancer has shown to have a favorable PFS. Patients were followed until death or from 7.5 months to 63.6 months (median 25.6 months) in those alive at last evaluation.

Groups in this outcome

Single Arm: Chemotherapy With Concurrent Radiation Therapy

Nab-Paclitaxel, Cetuximab, Cisplatin, and Intensity-modulated radiation therapy (IMRT)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Single Arm: Chemotherapy With Concurrent Radiation Therapy33

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Single Arm: Chemotherapy With Concurrent Radiation Therapy60Not reported4278Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        42
        upper Limit
        78
        value
        60
denoms
  1. counts
    1. group Id
      OG000
      value
      33
    units
    Participants
description
The 2-year PFS was measured from the date of enrollment to the first occurrence of new metastatic lesions, objective tumor progression, or death. The combination of cisplatin and cetuximab concurrent with radiation therapy for head and neck cancer has shown to have a favorable PFS. Patients were followed until death or from 7.5 months to 63.6 months (median 25.6 months) in those alive at last evaluation.
dispersion Type
95% Confidence Interval
groups
  1. description
    Nab-Paclitaxel, Cetuximab, Cisplatin, and Intensity-modulated radiation therapy (IMRT)
    id
    OG000
    title
    Single Arm: Chemotherapy With Concurrent Radiation Therapy
param Type
NUMBER
reporting Status
POSTED
time Frame
2 year from the date of enrollment
title
Progression Free Survival (PFS)
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice